IHI — iShares U.S. Medical Devices ET

Is IHI overbought or oversold? Here is the current MarketMoodz read.

ETF

Overbought As of August 19, 2026

iShares U.S. Medical Devices ET (IHI) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The ETF name last closed at $55.44. The rating moved from Neutral to Overbought on August 8, 2026.

See all overbought ETF stocks →

AI analysis

The iShares U.S. Medical Devices ET offers diversified, liquid exposure to a resilient healthcare subsector supported by demographic tailwinds and steady procedure-driven demand. Near-term catalysts include stable earnings and rotation away from extreme defensiveness as markets show mild risk-on behavior. Key vulnerabilities include sensitivity to elective procedure trends, regulatory/reimbursement outcomes, and potential market volatility that could drive ETF flows.

Key factors

  • Broad exposure to leading U.S. medical-device manufacturers providing diversified exposure to durable healthcare demand
  • Defensive demand drivers: aging populations, demographic tailwinds, and ongoing demand for elective and chronic-care procedures
  • Relative earnings resilience versus cyclical sectors during modest macro slowdowns
  • ETF structure offers low-cost, liquid access to the medical-device segment for portfolio allocation
  • Recent mild market risk-on tone reduces immediate headwinds from rate-driven sector rotation, supporting modest upside
  • Valuation and yield environment: medical device stocks often show stable margins and free-cash-flow conversion that support medium-term upside

Risks

  • Procedure volumes and device sales can be sensitive to macro and policy-driven delays in elective surgeries
  • Regulatory and reimbursement risk for device approvals and hospital procurement cycles
  • High long-term yields and options-market complacency could pressure equity ETFs if volatility spikes
  • Geopolitical headlines or broader risk-off events could trigger short-term ETF outflows
  • Concentration risk in top holdings within the ETF could amplify idiosyncratic company setbacks
  • Supply-chain disruptions or component shortages could squeeze margins and delay product launches

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for IHI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.